CHICAGO -- Pancreatic cancer patients with resectable disease who were treated with modified FOLFIRINOX lived a median of 20 months longer and were cancer-free 9 months longer than those treated with gemcitabine alone, setting a new standard of care for these patients, according to a here.
In this exclusive 乌鸦传媒 video, four specialists -- Robert J. Mayer, MD, of Dana-Farber Cancer Institute, Autumn McRee, MD, of the Lineberger Comprehensive Cancer Center at the University of North Carolina; Heinz-Josef Lenz, MD, of the University of Southern California's Keck School of Medicine; and Vincent Chung, MD, of City of Hope in Duarte, Calif. -- break down the findings and their impact on patients with this difficult-to-treat cancer.
Disclosures
Mayer disclosed relationships with Taiho Pharmaceutical and CASI Pharmaceuticals. Chung disclosed relationships with Celgene, Five Prime Therapeutics, Ipsen, and Perthera. Lenz reported ties with Bayer, Boehringer Ingelheim, Merck Serono, Roche, and Pfizer.
McRee reported no relationship with industry.
Primary Source
American Society of Clinical Oncology
Conroy T, et al "Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas" ASCO 2018; Abstract LBA4001.